Skip to main content
Equibles
WST logo

WST · West Pharmaceutical Services Inc · Metrics

Track WST — free

Use WST with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research WST.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$393.48 +4.70 (+1.21%) At close · Oct 21
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$27.73B
Shares
70.38M
Volume · Oct 21 574.16K Avg daily vol (3M) 603.78K

WST metrics

121 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$393.48
Market cap
$27.73B

Price action

20 metrics
Price change (1W)
+4.6%
Price change (30D)
+7.5%
Price change (3M)
+8.2%
Price change (6M)
+41.5%
Price change (YTD)
+41.3%
Price change (1Y)
+41.4%
Trailing year
Price change (5Y)
-6.2%
52-week high
$388.78
52-week low
$230.95
Change from 52-week high
+0.0%
Change from 52-week low
+68.3%
Annualized volatility
33.5%
Annualized volatility (3M)
25.1%
Beta
0.6
RSI (14D)
68.5
Price vs SMA 50
+8.2%
Price vs SMA 200
+26.1%
Avg volume (3M)
606,528
Relative volume
0.9
Average dollar volume
$215.33M

Company

3 metrics
Sector
Healthcare
Industry
Medical Instruments & Supplies
Shares outstanding
70.38M

Valuation

12 metrics
P / E (TTM)
49.8
Trailing earnings · reciprocal yield 2.0%
PEG ratio
2.7
EV / revenue
8.1×
reciprocal yield 12.3%
EV / EBITDA
31.4×
reciprocal yield 3.2%
EV / EBIT
39.8×
reciprocal yield 2.5%
P / sales
8.2×
reciprocal yield 12.2%
P / book
9.1
reciprocal yield 10.9%
FCF yield
1.6%
TTM · current market cap
Buyback yield
1.7%
P / FCF
62.5
reciprocal yield 1.6%
P / operating cash flow
41.2
reciprocal yield 2.4%
Earnings yield
2.1%

Historical valuation

8 metrics
P / E historical average (3Y)
42.5×
reciprocal yield 2.4%
P / E historical average (5Y)
42.7×
reciprocal yield 2.3%
EV / revenue historical average (3Y)
7.2×
reciprocal yield 13.9%
EV / revenue historical average (5Y)
7.9×
reciprocal yield 12.7%
EV / EBIT historical average (3Y)
34.7×
reciprocal yield 2.9%
EV / EBIT historical average (5Y)
34.8×
reciprocal yield 2.9%
EV / EBITDA historical average (3Y)
25.6×
reciprocal yield 3.9%
EV / EBITDA historical average (5Y)
25.6×
reciprocal yield 3.9%

Dividends & buybacks

7 metrics
Dividend yield
0.2%
Trailing 12 months
Payout ratio
11.0%
Shareholder yield
1.9%
Dividend / share (TTM)
$0.88
Dividend growth YoY
+4.8%
Dividend growth streak
5+
Stored dividend history starts 2020
Last ex-dividend
2026-07-29

Earnings calendar

2 metrics
Next earnings
2026-10-29
Last earnings
2026-07-23

Profitability

9 metrics
Gross margin
36.8%
Operating margin
20.5%
Trailing 12 months
Net margin
17.0%
Gross profit (TTM)
$1.22B
Operating profit (TTM)
$680.40M
Net income (TTM)
$564.90M
Trailing 12 months
Diluted EPS (TTM)
$7.81
FCF margin
13.1%
Effective tax rate
20.8%

Per share

11 metrics
Revenue per diluted share (TTM)
$46.06
Gross profit per diluted share (TTM)
$16.94
Operating profit per diluted share (TTM)
$9.42
EBITDA per diluted share (TTM)
$11.93
Net income per diluted share (TTM)
$7.82
Operating cash flow per diluted share (TTM)
$9.15
Free cash flow per diluted share (TTM)
$6.04
Capital expenditures per diluted share (TTM)
$3.11
R&D per diluted share (TTM)
$1.03
Stock compensation per diluted share (TTM)
$0.45
Book value per share
$44.11

Growth

11 metrics
Revenue growth YoY
+13.8%
Year over year
Net income growth YoY
+16.8%
Revenue (TTM)
$3.33B
Trailing 12 months
EPS growth YoY
+18.1%
Shares change YoY
-1.7%
Year over year · fewer shares
Revenue CAGR (3Y)
+2.1%
Revenue CAGR (5Y)
+7.4%
EPS CAGR (3Y)
-4.2%
EPS CAGR (5Y)
+8.2%
FCF CAGR (3Y)
+2.2%
FCF CAGR (5Y)
+9.5%

Quality

14 metrics
Return on equity
18.9%
Return on assets
13.9%
Debt / equity
0.1
Current ratio
2.8
EBITDA (TTM)
$861.80M
Free cash flow (TTM)
$436.90M
Quick ratio
2.1
Interest coverage
151.2
Net debt / EBITDA
-0.3
Return on invested capital
19.5%
Trailing 12 months
Net cash
$232.90M
Latest balance sheet
Cash & equivalents
$435.80M
Total assets
$4.08B
Total debt
$202.90M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$662.20M
Capital expenditures (TTM)
$225.30M
R&D (TTM)
$74.40M
SG&A (TTM)
$426.80M
Stock compensation (TTM)
$32.60M
R&D / revenue
2.2%
Stock compensation / revenue
1.0%

Ownership (13F)

9 metrics
13F filers
836
13F filer change QoQ
+77
Institutional ownership
100.6%
Conviction holders (share of 13F filers)
1.0%
Crowding (high-turnover and private-fund holders)
18.7%
Private-fund adviser ownership
18.1%
Active holders' share change QoQ
-1.6%
Holder tenure
16.9
Price vs estimated holder cost
+31.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
24.4%

Short interest

3 metrics
Short interest
3.0%
Latest settlement · 3.1 days to cover
Days to cover
3.1d
Short-squeeze score
59 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$5.44M
Insider-sentiment score
36 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 105770 CUSIP 955306105 13F (30d) 153 filings 148 filers Visit website Investor relations